Cargando…

Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment

OBJECTIVE: To evaluate the impact of enzyme replacement therapy for Gaucher Disease on clinical and laboratory parameters after two, five and ten years of treatment. METHODS: Data were collected from patient records and analyzed using BioEstat software (version 5.0). Student's t-test, Analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Souza, Ana Maria Almeida, Muniz, Thiago Pimentel, Brito, Rafael Maciel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318376/ https://www.ncbi.nlm.nih.gov/pubmed/25305167 http://dx.doi.org/10.1016/j.bjhh.2014.05.005

Ejemplares similares

Enzyme Replacement in Gaucher Disease
por: Beutler, Ernest
Publicado: (2004)

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
por: van Dussen, Laura, et al.
Publicado: (2014)

MiRNA Expression in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
por: Pawliński, Łukasz, et al.
Publicado: (2020)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Twenty- five years of biochemical diagnosis of Gaucher disease: the Egyptian experience
por: Fateen, Ekram, et al.
Publicado: (2019)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
por: Chauhan, Kanchan, et al.
Publicado: (2022)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
por: Dardis, A., et al.
Publicado: (2022)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Down-regulation of Regulatory T-cells in Children With Gaucher Disease Under Enzyme Replacement Therapy
por: Zahran, Asmaa M., et al.
Publicado: (2019)

Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment
por: Iaccarino Idelson, Paola, et al.
Publicado: (2022)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
por: Moraitou, Marina, et al.
Publicado: (2023)

Hematopoietic Stem Cell Transplantation is a cost-effective alternative to enzyme replacement therapy in Gaucher Disease
por: Aboobacker, Fouzia N, et al.
Publicado: (2022)

Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
por: Machaczka, Maciej, et al.
Publicado: (2014)

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model
por: Vigan, Marie, et al.
Publicado: (2014)

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients
por: Smid, Bouwien E., et al.
Publicado: (2016)

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
por: van Dussen, Laura, et al.
Publicado: (2014)

Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018)

Symmetric, bilateral upper and lower extremity lucent lesions in a patient with Gaucher's disease on enzyme replacement therapy
por: Kuhn, Andrew S., et al.
Publicado: (2020)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report
por: Uşurelu, Natalia, et al.
Publicado: (2021)

Oxidative stress parameters of Gaucher disease type I patients
por: Mello, Alexandre Silva, et al.
Publicado: (2015)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report
por: Vujosevic, Snezana, et al.
Publicado: (2019)

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously
por: Noya, MSoledad, et al.
Publicado: (2018)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
por: Kim, Yoo-Mi, et al.
Publicado: (2017)

Replacement Therapy for Gaucher Disease during Pregnancy: A Case Report
por: Giannubilo, Stefano Raffaele, et al.
Publicado: (2015)

Scoring system to facilitate diagnosis of Gaucher disease
por: Mehta, Atul, et al.
Publicado: (2020)

Coagulation Parameters in Adult Patients With Type-1 Gaucher Disease
por: Serratrice, Christine, et al.
Publicado: (2019)

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
por: Hughes, Derralynn A, et al.
Publicado: (2015)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

A case with Gaucher disease unable to reach enzyme replacement therapy because of COVID-19 quarantine: The first case from Turkey
por: Yekedüz, Merve Koç, et al.
Publicado: (2021)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kr1485g00fav7ls0t6vcs9fr9j